Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Screening of anti-metastasis drugs by targeting angiopellosis and cancer cluster extravasation.
Journal: Science advances
Published: August 19, 2026
Inflammatory Myofibroblastic Tumor: A Case Report of Neoadjuvant Alectinib and Summary of Single-Institution Molecular Data.
Journal: JCO precision oncology
Published: June 08, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.
Journal: Journal for immunotherapy of cancer
Published: May 19, 2026
Aneuploidy sensitizes cells to SREBP-pathway inhibition in squamous cell carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: May 18, 2026
Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor-Induced Autoimmunity.
Journal: ACR open rheumatology
Published: January 23, 2026
Hydrophobic complementarity-determining region 3 (CDR3) sequences elucidate the cardiotoxic effects of immune checkpoint inhibitors.
Journal: Research square
Published: January 09, 2026
Editorial: Nature and nurture in early onset lung cancer.
Journal: Frontiers in oncology
Published: November 20, 2025
Female sex is associated with worse survival in laryngeal head and neck squamous cell carcinoma.
Journal: The oncologist
Published: June 05, 2025
The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non-small cell lung cancer.
Journal: Journal of the National Cancer Institute
Published: April 24, 2025
Central Nervous System Metastases from Primary Lung Carcinoma: Significance of RNA Fusion Testing and Early Versus Late Metastases.
Journal: Journal of personalized medicine
Published: February 25, 2025
Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells.
Journal: Journal for immunotherapy of cancer
Published: February 18, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 27, 2025
Last Updated: 09/26/2026